UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): September 15, 2010
CELLDEX THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in its Charter)
|
Delaware |
|
0-15006 |
|
13-3191702 |
|
(State or Other Jurisdiction |
|
(Commission File Number) |
|
(IRS Employer |
|
of Incorporation) |
|
|
|
Identification No.) |
|
119 Fourth Avenue |
|
|
|
Needham, Massachusetts |
|
02494-2725 |
|
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (781) 433-0771
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.07. Submission of Matters to a Vote of Security Holders
Our annual meeting of shareholders was held on September 15, 2010. Our shareholders elected the following individuals to serve on our board of directors until the annual meeting of shareholders to be held in 2011. The tabulation of votes with respect to the election of such directors was as follows:
|
|
|
For |
|
Withheld |
|
|
Larry Ellberger |
|
8,387,626 |
|
503,008 |
|
|
Anthony S. Marucci |
|
8,442,095 |
|
448,539 |
|
|
Herbert J. Conrad |
|
8,384,923 |
|
505,711 |
|
|
George O. Elston |
|
8,471,315 |
|
419,319 |
|
|
Karen Shoos Lipton |
|
8,389,578 |
|
501,056 |
|
|
Dr. Rajesh B. Parekh. |
|
8,191,820 |
|
698,814 |
|
|
Harry H. Penner, Jr. |
|
8,203,349 |
|
687,285 |
|
|
Dr. Timothy M. Shannon |
|
8,485,447 |
|
405,187 |
|
In addition, our shareholders approved the ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2010. The tabulation of votes with respect to this proposal was as follows:
|
For |
|
Against |
|
Abstain |
|
Broker |
|
|
23,869,786 |
|
1,199,370 |
|
113,208 |
|
— |
|
With the election of the above-referenced board members on September 15, 2010, Charles Schaller’s term of service on our board of directors ended. The board of directors of Celldex wishes to express its gratitude to Mr. Schaller for the dedication and guidance he has provided to this company and its board of directors over the years.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
CELLDEX THERAPEUTICS, INC. |
|
|
|
|
|
|
|
|
|
|
|
By: |
/s/ Avery W. Catlin |
|
|
|
Name: Avery W. Catlin |
|
|
|
Title: Senior Vice President / Chief Financial Officer |
Dated: September 16, 2010